[HTML][HTML] Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus
C Fanton, R Furie, V Chindalore, R Levin, I Diab… - Journal of Translational …, 2022 - Elsevier
Objective To evaluate NKTR-358, a polyethylene glycol-interleukin-2 conjugate composition
designed to selectively induce regulatory T cells (Tregs), in first-in-human studies. Methods …
designed to selectively induce regulatory T cells (Tregs), in first-in-human studies. Methods …
Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus.
C Fanton, R Furie, V Chindalore, R Levin… - Journal of …, 2022 - europepmc.org
Objective To evaluate NKTR-358, a polyethylene glycol-interleukin-2 conjugate composition
designed to selectively induce regulatory T cells (Tregs), in first-in-human studies. Methods …
designed to selectively induce regulatory T cells (Tregs), in first-in-human studies. Methods …
Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus
C Fanton, R Furie, V Chindalore… - Journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
Objective To evaluate NKTR-358, a polyethylene glycol-interleukin-2 conjugate composition
designed to selectively induce regulatory T cells (Tregs), in first-in-human studies. Methods …
designed to selectively induce regulatory T cells (Tregs), in first-in-human studies. Methods …
[HTML][HTML] Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus
C Fanton, R Furie, V Chindalore, R Levin… - Journal of …, 2022 - ncbi.nlm.nih.gov
Objective To evaluate NKTR-358, a polyethylene glycol-interleukin-2 conjugate composition
designed to selectively induce regulatory T cells (Tregs), in first-in-human studies. Methods …
designed to selectively induce regulatory T cells (Tregs), in first-in-human studies. Methods …